Research Analysts Issue Forecasts for Ocugen FY2026 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at Noble Financial lifted their FY2026 earnings per share estimates for Ocugen in a research report issued to clients and investors on Wednesday, November 11th. Noble Financial analyst R. Leboyer now expects that the company will earn ($0.16) per share for the year, up from their prior estimate of ($0.26). The consensus estimate for Ocugen’s current full-year earnings is ($0.23) per share.

A number of other research firms have also recently issued reports on OCGN. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocugen in a research report on Wednesday, November 4th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Ocugen Price Performance

Shares of NASDAQ OCGN opened at $0.87 on Friday. Ocugen has a fifty-two week low of $0.69 and a fifty-two week high of $2.73. The company has a current ratio of 0.77, a quick ratio of 0.77 and a debt-to-equity ratio of 4.17. The business’s 50 day moving average price is $0.95 and its 200-day moving average price is $1.39.

Insider Transactions at Ocugen

In other Ocugen news, CEO Shankar Musunuri sold 57,264 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $0.95, for a total value of $54,400.80. Following the transaction, the chief executive officer directly owned 1,030,771 shares in the company, valued at $979,232.45. This represents a 5.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,051,982 shares of company stock valued at $1,088,801. 3.95% of the stock is owned by insiders.

Institutional Trading of Ocugen

Institutional investors and hedge funds have recently modified their holdings of the stock. Diversify Advisory Services LLC purchased a new stake in shares of Ocugen in the second quarter valued at approximately $25,000. GTS Securities LLC purchased a new position in Ocugen during the 2nd quarter worth $27,000. Engineers Gate Manager LP increased its holdings in Ocugen by 70.2% during the 2nd quarter. Engineers Gate Manager LP now owns 18,368 shares of the company’s stock worth $28,000 after purchasing an additional 7,577 shares during the period. CTC Alternative Strategies Ltd. bought a new stake in Ocugen during the 1st quarter valued at $34,000. Finally, Legal & General Group Plc bought a new stake in Ocugen during the 2nd quarter valued at $51,000. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases and other eye conditions. Its approach includes modifier gene therapies designed to address multiple genetic causes of disease, rather than targeting a single mutation. The company’s clinical programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease. These programs are investigational and are not approved treatments.